Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4389817 | 0.83 | CYP4F2 (0.54) | NOS2NAMPTSMN1; SMN2TDP1HSD17B10 | |
| Hydrochloric Acid SCHEMBL31517445 | 0.80 | NOS2 (0.56) | NOS2NAMPTSMN1; SMN2HSD17B10 | |
| SCHEMBL11786237 | 0.78 | NOS2 (0.46) | NOS2NAMPTSMN1; SMN2PKMTDP1 | |
| SCHEMBL25122833 | 0.77 | NOS2 (0.53) | NOS2NAMPT | |
| SCHEMBL24690844 | 0.77 | — | — | |
| SCHEMBL5739940 | 0.77 | KMT2A (0.44) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL27381872 | 0.76 | ALDH1A1 (0.47) | NOS2NAMPTSMN1; SMN2KMT2AHSD17B10 | |
| Ethyl Acetate SCHEMBL28597398 | 0.75 | ALDH1A1 (0.45) | NOS2NAMPTPKMKMT2AHSD17B10 | |
| SCHEMBL3090700 | 0.75 | NAMPT (0.43) | NOS2NAMPTKMT2A | |
| SCHEMBL27376858 | 0.74 | NOS2 (0.43) | NOS2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497382-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| WO-2025040546-A1 | PYRAZOLE COMPOUNDS AS CULLIN RING UBIQUITIN LIGASE COMPOUNDS | PROXYGEN GMBH (AT) | 2025-02-27 | — | — | WO | disclosed |
| US-20230391747-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-12-07 | — | — | US | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| CN-115867284-A | Heterocyclic compounds as trigger receptor 2 agonists expressed on myeloid cells and methods of use | 安进公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4048664-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-114630823-A | GLP-1R modulating compounds | 吉利德科学公司 | 2022-06-14 | — | — | CN | disclosed |
| US-20210171499-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210171499-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2021081207-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021081207-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-20090306059-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| CN-101233108-A | Cyclic amine derivative having substituted alkyl group | DAIICHI SANKYO CO LTD (JP) | 2008-07-30 | — | — | CN | disclosed |
| EP-1889835-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2008-02-20 | — | — | EP | disclosed |
| CN-1956971-A | Novel fused heterocycles and application thereof | ASTRAZENECA AB (SE) | 2007-05-02 | — | — | CN | disclosed |
| US-4325962-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIDYRETICS | BYK-GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1982-04-20 | — | — | US | disclosed |
| US-4146721-A | ANALGESICS, ANTIINFLAMMATORY AGENTS AND ANTIPYRETICS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702404-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | NOS2 4216/4885NAMPT 1471/4885SMN1; SMN2 1956/4885 |
| US-20230391747-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | NOS2 4216/4885NAMPT 1471/4885SMN1; SMN2 1956/4885 |
| US-20210171499-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | NOS2 4216/4885NAMPT 1471/4885SMN1; SMN2 1956/4885 |
| US-12497382-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | NOS2 4216/4885NAMPT 1471/4885SMN1; SMN2 1956/4885 |
| US-20090306059-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | CBR3, CNR1, C3AR1 | NOS2 588/4885NAMPT 3064/4885SMN1; SMN2 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.